Researchers from Roswell Park Comprehensive Cancer Center uncovered a previously unknown function of a gene that regulates the p53 protein, mutations of which have been linked to a wide variety of cancers.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
